医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Cardiac IVD Company Critical Diagnostics Continues Asia Pacific Push

2012年12月03日 PM11:40
このエントリーをはてなブックマークに追加


 

SAN DIEGO

Critical Diagnostics, a U.S.-based biomarker company focused on cardiovascular diseases, and makers of the Presage® ST2 Assay, today announced the addition of four new distributor relationships.

The Company has chosen Integrated Sciences as its exclusive distributor in Australia, United Laboratories in the Philippines and IDS Medical Systems/Malaysia in Malaysia and IDS Medical Systems/Singapore in Singapore.

“These new associations, together with our existing distribution partners, mean that some three billion people, or half the world’s population, will now have access to the Presage ST2 Assay,” notes James Snider, President of Critical Diagnostics. “And interest from distributors around the world continues to pour in.”

About Integrated Sciences

Headquartered in Sydney, with offices in the major cities of Australia, Integrated Sciences boasts greater 25 years experience in the Australian diagnostics and life sciences markets.

About United Laboratories

United Laboratories, founded in 1945, is the largest pharmaceutical company in the Philippines and serves more than 1,000 cardiologists. Unilab also has significant and growing market share in the broader Asia-Pacific region.

About IDS Medical Systems

Part of Hong Kong-based Li & Fung Group, IDS Medical Systems Malaysia and IDS Medical Systems Singapore, are integrated medical solutions providers focused on cardiovascular medicine. The company has over 20 years of experience in both Malaysia and Singapore.

About ST2

Soluble ST2 has now been published in more than 100 peer-reviewed articles and scientific posters studying more than 35,000 patients. These clinical studies have demonstrated that high levels of soluble ST2 are predictive of adverse patient outcomes and death in a broad spectrum of cardiovascular disease. They have further shown that the prognostic information from soluble ST2 is independent and provides added information to cardiac biomarkers commonly used today, including the natriuretic peptides, BNP and NT-proBNP.

About Critical Diagnostics and ST2

Critical Diagnostics (www.criticaldiagnostics.com) develops novel biomarkers to help physicians optimize patient care in cardiovascular diseases, while containing healthcare costs. The Presage ST2 Assay has been CE Marked and cleared by the US FDA for use in risk stratification with chronic heart failure patients. Critical Diagnostics has exclusive worldwide rights to ST2 for the diagnosis and prognosis of cardiovascular disease.

CONTACT

Critical Diagnostics
Dennis Dalangin, 877-700-1250
VP Marketing
ddalangin@criticaldiagnostics.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • PotNetwork Holdings, Inc.在注册成为SEC报告公司之后发布PCAOB经审计和审核的完整财务报表
  • PotNetwork Holdings, Inc.提交Form 10以成为美国证券交易委员会报告公司
  • レスメド初の最小接触面フルフェイスCPAPマスクAirFit F30を米国とカナダで販売開始
  • Foundation Medicine Announces Strategic Collaboration with Major Pharmaceutical Company
  • Biogen and Samsung Bioepis Announce European Launch of IMRALDI™(adalimumab), Solidifying Leadership in European Anti-TNF Market